Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab

CD38-targeted antibody, daratumumab, is approved for the treatment of multiple myeloma (MM). Phase 1/2 studies GEN501/SIRIUS revealed a novel immunomodulatory mechanism of action (MOA) of daratumumab that enhanced the immune response, reducing natural killer (NK) cells without affecting efficacy or...

Descripción completa

Detalles Bibliográficos
Autores principales: Casneuf, Tineke, Adams, Homer C., van de Donk, Niels W.C.J., Abraham, Yann, Bald, Jaime, Vanhoof, Greet, Van der Borght, Koen, Smets, Tina, Foulk, Brad, Nielsen, Karl C., Rusbuldt, Joshua, Axel, Amy, Lysaght, Andrew, Ceulemans, Hugo, Stevenaert, Frederik, Usmani, Saad Z., Plesner, Torben, Avet-Loiseau, Herve, Nijhof, Inger, Mutis, Tuna, Schecter, Jordan M., Chiu, Christopher, Bahlis, Nizar J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862054/
https://www.ncbi.nlm.nih.gov/pubmed/32457357
http://dx.doi.org/10.1038/s41375-020-0855-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862054/
https://www.ncbi.nlm.nih.gov/pubmed/32457357
http://dx.doi.org/10.1038/s41375-020-0855-4

Ejemplares similares